1. Home
  2. SGMO vs NYXH Comparison

SGMO vs NYXH Comparison

Compare SGMO & NYXH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Sangamo Therapeutics Inc.

SGMO

Sangamo Therapeutics Inc.

HOLD

Current Price

$0.26

Market Cap

141.2M

Sector

Health Care

ML Signal

HOLD

Logo Nyxoah SA

NYXH

Nyxoah SA

HOLD

Current Price

$2.82

Market Cap

152.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SGMO
NYXH
Founded
1995
2009
Country
United States
Belgium
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Medical/Dental Instruments
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
141.2M
152.8M
IPO Year
2000
2021

Fundamental Metrics

Financial Performance
Metric
SGMO
NYXH
Price
$0.26
$2.82
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
3
3
Target Price
$7.00
$9.33
AVG Volume (30 Days)
7.4M
53.9K
Earning Date
05-11-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
10.20
N/A
EPS
N/A
N/A
Revenue
$36,567,000.00
N/A
Revenue This Year
$24.46
$214.32
Revenue Next Year
$193.67
$124.13
P/E Ratio
N/A
N/A
Revenue Growth
88.60
N/A
52 Week Low
$0.21
$2.76
52 Week High
$0.84
$8.64

Technical Indicators

Market Signals
Indicator
SGMO
NYXH
Relative Strength Index (RSI) 35.23 36.49
Support Level $0.21 $2.76
Resistance Level $0.55 $5.02
Average True Range (ATR) 0.04 0.18
MACD -0.00 0.03
Stochastic Oscillator 25.91 8.52

Price Performance

Historical Comparison
SGMO
NYXH

About SGMO Sangamo Therapeutics Inc.

Sangamo Therapeutics Inc is a genomic medicine company committed to translating ground-breaking science into medicines that transform the lives of patients and families afflicted with serious neurological diseases. Its pipeline products include the Priority Neurology Pipeline offers Chronic Neuropathic Pain, Prion Disease, and Neurology; Partnered Programs offer Hemophilia A, Oncology, ALS/FTD, and Huntington's Disease; and Other Pipelines include Fabry Disease, Renal Transplant, Inflammatory Bowel Disease, and Multiple Sclerosis.

About NYXH Nyxoah SA

Nyxoah SA is a health-technology company focused on the development and commercialization of solutions and services to treat sleep-disordered breathing conditions. The company's solution platform is based on the Genio system, a CE-Mark validated, user-centered, bilateral neurostimulation therapy to treat moderate to severe Obstructive Sleep Apnea (OSA), the common sleep disordered breathing condition that is associated with increased mortality risk and comorbidities including cardiovascular diseases, depression and stroke.

Share on Social Networks: